Naloxone Co-Prescribing in PI Cases: Standard of Care Evidence

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 7 min read

Naloxone co-prescribing with opioids is now the standard of care nationally, and its presence in PI pharmacy records documents treatment severity, prescriber diligence, and opioid-level pain management. This guide explains why naloxone matters for settlement documentation.

Naloxone co-prescribing is the practice of prescribing naloxone (Narcan) alongside opioid medications as a safety measure against potential overdose, and it has become the national standard of care for any patient receiving opioid therapy — a clinical fact that transforms naloxone from a background medication into powerful settlement documentation in personal injury cases. When naloxone appears in the pharmacy record alongside opioid prescriptions, it confirms that the patient's injuries required opioid-level pain management serious enough to warrant overdose prevention measures.

• Naloxone (brand name Narcan) is an opioid antagonist that rapidly reverses opioid overdose, and its co-prescription with opioids is recommended by the CDC, FDA, AMA, and virtually every state medical board as standard of care (CDC Clinical Practice Guideline for Prescribing Opioids, 2022)
• The FDA issued a Drug Safety Communication in 2020 recommending naloxone co-prescribing for all patients receiving opioids, particularly those on higher doses (>=50 MME/day), concurrent benzodiazepines, or with respiratory risk factors
• LienScripts dispenses naloxone alongside opioid prescriptions on pharmacy lien and documents the co-prescription in the MERIT (Medication Evaluation & Rationale for Injury Treatment) report as evidence of treatment severity
• According to James Wong, PharmD, founder of LienScripts, "Naloxone co-prescribing is the clearest signal in a pharmacy record that the prescriber assessed the patient's opioid therapy as clinically significant — it documents severity in a way that the opioid prescription alone does not"
• Over 30 states have enacted laws mandating or encouraging naloxone co-prescribing with opioids, and the practice is endorsed as Tier 1 evidence by the U.S. Preventive Services Task Force

Why Naloxone Appears in PI Pharmacy Records

Naloxone co-prescribing is triggered by specific clinical factors, all of which are relevant to settlement valuation:

High-Dose Opioid Therapy

The CDC recommends naloxone co-prescribing for patients receiving opioid dosages of 50 morphine milligram equivalents (MME) per day or higher. If the patient's injuries required opioid therapy at or above this threshold, the naloxone confirms the dosage level — a fact with direct relevance to both special and general damages.

Concurrent Benzodiazepine Use

Many PI patients receive benzodiazepines (Valium, Ativan, Klonopin) for muscle spasm, anxiety, or sleep disturbance alongside their opioid therapy. The FDA issued a boxed warning about the combined respiratory depression risk. Naloxone co-prescribing in this context documents multi-drug therapy driven by multi-symptom injury impact.

Extended Duration of Opioid Use

Patients on opioid therapy for extended periods face cumulative risk. Naloxone co-prescribing after months of opioid therapy documents the ongoing nature of the pain condition and the prescriber's assessment that the patient's treatment requires continued opioid management with safety precautions.

[!KEY] Naloxone in the pharmacy record is not evidence that the patient is at fault or engaging in risky behavior. It is evidence that the prescriber is following the standard of care for opioid therapy — and by extension, that the patient's injuries required the level of opioid therapy that triggers naloxone co-prescribing guidelines.

The Documentation Power of Naloxone

For attorneys, naloxone provides several documentation advantages:

1. Objective Severity Marker

Naloxone co-prescribing is triggered by specific, quantifiable clinical criteria (dose thresholds, concurrent medications, duration). Its presence is an objective marker of treatment intensity — not a subjective complaint, but a clinical response to measured risk factors.

2. Standard of Care Compliance

A prescriber who co-prescribes naloxone is following national guidelines. This protects the treatment record from defense attacks suggesting that the opioid therapy was inappropriate or excessive — the prescriber was clearly monitoring risk and implementing safety measures.

3. Multi-System Injury Documentation

When naloxone is co-prescribed because the patient receives both opioids and benzodiazepines, the pharmacy record documents multi-system injury impact: pain requiring opioids AND anxiety/spasm requiring benzodiazepines AND combined risk requiring naloxone. Three medications documenting three layers of injury consequence.

[!TIP] In the demand package, present naloxone co-prescribing as a clinical severity indicator. A statement such as "The treating physician determined that the patient's opioid therapy was of sufficient intensity to warrant co-prescribing naloxone for overdose prevention per CDC guidelines" communicates severity more effectively than listing drug names and doses.

Naloxone Formulations and Access

Naloxone is available in several formulations relevant to PI cases:

Narcan Nasal Spray (4mg) — The most commonly prescribed formulation. In 2023, the FDA approved over-the-counter Narcan, but prescription naloxone co-prescribed with opioids remains a documented clinical intervention.

Generic naloxone nasal spray — Less expensive alternatives that serve the same clinical purpose and carry the same documentation value.

Naloxone auto-injector (Evzio) — A voice-guided auto-injector designed for layperson use. Less commonly prescribed due to cost but clinically equivalent.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The specific naloxone formulation matters less than the fact that it was prescribed. Whether it is Narcan nasal spray or generic naloxone, the clinical message is identical: the prescriber assessed this patient's opioid therapy as carrying meaningful risk and took the standard-of-care step to mitigate it."

Insurance and Pharmacy Lien Coverage

Despite its safety-critical role, naloxone faces access barriers:

• Cost — Narcan nasal spray can cost $40-140 per kit without insurance, which some patients forgo when already managing high medication costs
• Prior authorization — Some insurers require prior authorization for prescription naloxone, creating delays
• Patient stigma — Some patients resist filling naloxone prescriptions due to perceived stigma, which can create documentation gaps

LienScripts eliminates these barriers by dispensing naloxone as part of the opioid therapy package on pharmacy lien at no upfront cost to the patient. This ensures both patient safety and complete documentation.

Demand Package Strategy

When naloxone appears in the pharmacy record, attorneys should:

1. Identify the trigger — Determine why naloxone was co-prescribed (high dose, concurrent benzodiazepines, extended duration) and state it explicitly
2. Connect to injury — Draw the direct line: accident caused injuries, injuries required opioid therapy, opioid therapy required naloxone safety measures
3. Quantify the treatment burden — Naloxone is an additional medication, an additional pharmacy visit, and an additional reminder to the patient that their injuries carry life-threatening treatment risks
4. Use the MERIT report — The LienScripts MERIT report presents naloxone in the context of the full medication timeline, connecting it to the opioid prescriptions and clinical rationale

[!KEY] Naloxone co-prescribing converts a defense argument ("the opioid therapy was excessive") into a plaintiff argument ("the injuries required opioid therapy so serious that the national standard of care mandated overdose prevention"). This reframing is powerful in mediation and trial.

FAQs

Related Resources

• Opioid Prescribing Guidelines in Personal Injury Cases
• Opioid Rotation Therapy: Pharmacy Lien Strategy
• What Is a MERIT Report?
• Pain Management Doctor and Pharmacy Lien Coordination